Table 1. List of 37 differentially expressed genes in OSCC via comparison of the OSCC-OncoScan and OSCC-TCGA-DEG datasets
Gene name
|
CNV in
OncoScan
|
T/N in
OSCC-TCGA
|
Dysregulated in HNSCC (ref.)
|
p valuea of OS rate
in OSCC-TCGA
|
CSMD1
|
Del.
|
0.10
|
Yes [1]
|
|
DOCK3
|
Del.
|
0.32
|
|
0.14
|
FHIT
|
Del.
|
0.14
|
Yes [2]
|
|
KAT2B
|
Del.
|
0.31
|
|
0.58
|
LPL
|
Del.
|
0.30
|
Yes [3]
|
|
MITF
|
Del.
|
0.29
|
Yes [4]
|
|
NAT2
|
Del.
|
0.06
|
Yes [5]
|
|
PPARG
|
Del.
|
0.11
|
|
0.21
|
ROBO2
|
Del.
|
0.06
|
Yes [6]
|
|
SCARA5
|
Del.
|
0.18
|
|
0.098
|
SLC7A2
|
Del.
|
0.20
|
|
0.79
|
THRB
|
Del.
|
0.44
|
Yes [7]
|
|
ATP6V1C1
|
Amp.
|
2.03
|
Yes [8]
|
|
CSMD3
|
Amp.
|
66.29
|
Yes [9]
|
|
E2F1
|
Amp.
|
3.57
|
Yes [10]
|
|
EIF5A2
|
Amp.
|
3.41
|
Yes [11]
|
|
EXT1
|
Amp.
|
3.20
|
Yes [12]
|
|
FANCC
|
Amp.
|
2.06
|
Yes [13]
|
|
FANCG
|
Amp.
|
2.14
|
Yes [14]
|
|
GLI3
|
Amp.
|
2.08
|
|
0.78
|
HECW1
|
Amp.
|
2.36
|
|
0.48
|
HIF1A
|
Amp.
|
2.02
|
Yes [15]
|
|
IGFBP1
|
Amp.
|
78.17
|
Yes [16]
|
|
IGFBP3
|
Amp.
|
3.03
|
Yes [17]
|
|
INHBA
|
Amp.
|
28.45
|
Yes [18]
|
|
LEPREL1
|
Amp.
|
4.54
|
|
0.32
|
MFI2
|
Amp.
|
2.64
|
|
0.021b
|
PAX5
|
Amp.
|
11.83
|
Yes [19]
|
|
PCNA
|
Amp.
|
2.06
|
Yes [20]
|
|
PLEC
|
Amp.
|
2.18
|
Yes [21]
|
|
PRKDC
|
Amp.
|
2.00
|
Yes [22]
|
|
RCOR2
|
Amp.
|
2.59
|
|
0.23
|
RECQL4
|
Amp.
|
3.26
|
Yes [23]
|
|
ROR2
|
Amp.
|
3.46
|
Yes [24]
|
|
SOX12
|
Amp.
|
2.34
|
|
0.10
|
TFRC
|
Amp.
|
2.27
|
Yes [25]
|
|
TP63
|
Amp.
|
2.53
|
Yes [26]
|
|
Abbreviations: Amp., amplification; CNV, copy number variation; Del., deletion; T/N, tumor tissue sample and normal tissue sample; TCGA, The Cancer Genome Atlas; HNSCC, Head and neck squamous cell carcinoma
ap value is determined by the log-rank tests.
bThese are considered statistically significant.
|
[1] Toomes C, Jackson A, Maguire K, Wood J, Gollin S, Ishwad C, Paterson I, Prime S, Parkinson K, Bell S, Woods G, Markham A, Oliver R, Woodward R, Sloan P, Dixon M, Read A and Thakker N. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer 2003; 37: 132-140.
[2] Joo YH, Park SW, Jung SH, Lee YS, Nam IC, Cho KJ, Park JO, Chung YJ and Kim MS. Recurrent loss of the FHIT gene and its impact on lymphatic metastasis in early oral squamous cell carcinoma. Acta Otolaryngol 2013; 133: 992-999.
[3] Liu CJ, Lin SC, Chen YJ, Chang KM and Chang KW. Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 2006; 45: 721-731.
[4] Alaeddini M and Etemad-Moghadam S. Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma. J Oral Pathol Med 2015; 44: 234-238.
[5] Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL and Schwartz SM. N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 2001; 22: 1993-1999.
[6] Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roychoudhury S and Panda CK. Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. Hum Genet 2009; 125: 189-198.
[7] Rowley H, Jones A, Spandidos D and Field J. Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg 1996; 122: 497-501.
[8] Oliveira Alves MG, Carta CF, Padin-Iruegas ME, Perez-Sayans M, Suarez-Penaranda JM, Issa JS, Garcia-Garcia A and Almeida JD. Expression of ATP6V1C1 during oral carcinogenesis. Biotech Histochem 2016; 91: 263-268.
[9] Al-Hebshi NN, Li S, Nasher AT, El-Setouhy M, Alsanosi R, Blancato J and Loffredo C. Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes. Int J Cancer 2016; 139: 363-372.
[10] Wu ZH, Yun T and Cheng Q. Data Mining Identifies Six Proteins that Can Act as Prognostic Markers for Head and Neck Squamous Cell Carcinoma. Cell Transplant 2020; 29: 963689720929308.
[11] Fang L, Gao L, Xie L and Xiao G. GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells. Oncol Rep 2018; 39: 1283-1291.
[12] Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM and Chang KW. Genome-wide profiling of oral squamous cell carcinoma. J Pathol 2004; 204: 326-332.
[13] Ghosh A, Maiti GP, Bandopadhyay MN, Chakraborty J, Biswas J, Roychoudhury S and Panda CK. Inactivation of 9q22.3 tumor suppressor genes predict outcome for patients with head and neck squamous cell carcinoma. Anticancer Res 2013; 33: 1215-1220.
[14] Turke C, Horn S, Petto C, Labudde D, Lauer G and Wittenburg G. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity. Int J Oncol 2017; 50: 2207-2220.
[15] Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC and Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 1192-1202.
[16] Feng X, Lin J, Xing S, Liu W and Zhang G. Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer 2017; 17: 90.
[17] Sakata J, Hirosue A, Yoshida R, Matsuoka Y, Kawahara K, Arita H, Nakashima H, Yamamoto T, Nagata M, Kawaguchi S, Gohara S, Nagao Y, Yamana K, Toya R, Murakami R, Kuwahara Y, Fukumoto M and Nakayama H. Enhanced Expression of IGFBP-3 Reduces Radiosensitivity and Is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma. Cancers (Basel) 2020; 12:
[18] Chen YJ, Liao YJ, Lin F, Sun SG, Zhao XL, Qin JH and Rao SQ. [Shared functional modules for nasopharyngeal and oral squamous cell carcinoma identified by network analysis of transcriptomes]. Yi Chuan 2019; 41: 146-157.
[19] Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, Tanabe H, Takano N, Iwata N, Niwa Y, Takami H, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Fujii T, Fujiwara M and Kodera Y. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma. Epigenetics 2017; 12: 865-874.
[20] Zhao H, Chen M, Wang J, Cao G, Chen W and Xu J. PCNA-associated factor KIAA0101 transcriptionally induced by ELK1 controls cell proliferation and apoptosis in nasopharyngeal carcinoma: an integrated bioinformatics and experimental study. Aging (Albany NY) 2020; 12: 5992-6017.
[21] Pawar H, Kashyap MK, Sahasrabuddhe NA, Renuse S, Harsha HC, Kumar P, Sharma J, Kandasamy K, Marimuthu A, Nair B, Rajagopalan S, Maharudraiah J, Premalatha CS, Kumar KV, Vijayakumar M, Chaerkady R, Prasad TS, Kumar RV and Pandey A. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 2011; 12: 510-522.
[22] Dodd LE, Sengupta S, Chen IH, den Boon JA, Cheng YJ, Westra W, Newton MA, Mittl BF, McShane L, Chen CJ, Ahlquist P and Hildesheim A. Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 2216-2225.
[23] Yong ZW, Zaini ZM, Kallarakkal TG, Karen-Ng LP, Rahman ZA, Ismail SM, Sharifah NA, Mustafa WM, Abraham MT, Tay KK and Zain RB. Genetic alterations of chromosome 8 genes in oral cancer. Sci Rep 2014; 4: 6073.
[24] Sakamoto T, Kawano S, Matsubara R, Goto Y, Jinno T, Maruse Y, Kaneko N, Hashiguchi Y, Hattori T, Tanaka S, Kitamura R, Kiyoshima T and Nakamura S. Critical roles of Wnt5a-Ror2 signaling in aggressiveness of tongue squamous cell carcinoma and production of matrix metalloproteinase-2 via DeltaNp63beta-mediated epithelial-mesenchymal transition. Oral Oncol 2017; 69: 15-25.
[25] Wada S, Noguchi T, Takeno S and Kawahara K. PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma. Ann Surg Oncol 2006; 13: 961-966.
[26] King KE, George AL, Sakakibara N, Mahmood K, Moses MA and Weinberg WC. Intersection of the p63 and NF-kappaB pathways in epithelial homeostasis and disease. Mol Carcinog 2019; 58: 1571-1580.
Table 2. The clinicopathological characteristics related to the expression of MFI2 in 115 samples of OSCC
Patient categories
|
Case number
|
MFI2 expression level
|
|
Low (%)
|
High (%)
|
p value
|
Sex
|
|
|
|
|
Male
|
103
|
56 (54.4)
|
47 (45.6)
|
0.404
|
Female
|
12
|
5 (41.7)
|
7 (58.3)
|
|
Agea
Tumor classification
|
|
51.0 ± 10.8
(78.3, 22.5)
|
52.8 ± 13.4
(79.8, 20.3)
|
0.550
|
T1-T2
|
58
|
32 (55.2)
|
26 (44.8)
|
0.644
|
T3-T4
|
57
|
29 (50.9)
|
28 (49.1)
|
|
Node classification
|
|
|
|
|
0
|
55
|
36 (65.5)
|
19 (34.5)
|
0.011d
|
>0
|
60
|
25 (41.7)
|
35 (58.3)
|
|
Overall TNM stage
|
|
|
|
|
I-II
|
34
|
24 (70.6)
|
10 (29.4)
|
0.015d
|
III-IV
|
81
|
37 (45.7)
|
44 (54.3)
|
|
ENEb
|
|
|
|
|
No
|
84
|
48 (57.1)
|
36 (42.9)
|
0.147
|
Yes
|
31
|
13 (41.9)
|
18 (58.1)
|
|
PNIc
No
Yes
Differentiation
|
59
56
|
38 (64.4)
23 (41.1)
|
21 (35.6)
33 (58.9)
|
0.012d
|
Well + moderately
|
100
|
56 (56.0)
|
44 (44.0)
|
0.101
|
Poorly
Tumor depth
≤8mm
>8mm
|
15
44
71
|
5 (33.3)
24 (54.5)
37 (52.1)
|
10 (66.7)
20 (45.5)
34 (47.9)
|
0.799
|
aMean ± SD, (maximum, minimum)
bENE: extranodal extension
cPNI: perineural invasion
dThese are considered statistically significant.